| Followers | 843 |
| Posts | 122925 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Monday, May 26, 2025 6:03:59 PM
ABBV is not in vaccine business.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent ABBV News
- AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec • GlobeNewswire Inc. • 04/30/2026 07:00:00 PM
- Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month • PR Newswire (US) • 04/30/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:50:28 AM
- AbbVie Reports First-Quarter 2026 Financial Results • PR Newswire (US) • 04/29/2026 11:47:00 AM
- Markets Steady Ahead of Fed Decision and Key Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures • IH Market News • 04/29/2026 09:16:13 AM
- Markets Hold Steady Ahead of Fed Call and Big Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures • UK Market News • 04/29/2026 09:15:43 AM
- AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata • PR Newswire (US) • 04/28/2026 12:00:00 PM
- RINVOQ® (upadacitinib) s'est révélé supérieur à HUMIRA® (adalimumab) pour ce qui est du principal paramètre d'évaluation d'une étude comparative directe menée chez des patients atteints de polyarthrite rhumatoïde dont le premier traitement par • PR Newswire (Canada) • 04/28/2026 11:01:00 AM
- RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor • PR Newswire (Canada) • 04/28/2026 11:01:00 AM
- EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease • PR Newswire (US) • 04/27/2026 12:05:00 PM
- AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. • PR Newswire (US) • 04/23/2026 08:05:00 PM
- AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus • PR Newswire (US) • 04/22/2026 04:02:00 PM
- AbbVie et BioLabs unissent leurs forces pour appuyer l'innovation dans le secteur des sciences de la vie au Canada • PR Newswire (Canada) • 04/20/2026 07:00:00 PM
- AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada • PR Newswire (Canada) • 04/20/2026 07:00:00 PM
- Erin Lichy Gets Real About Her Natrelle® Breast Augmentation • PR Newswire (US) • 04/14/2026 12:50:00 PM
- AbbVie ends CollPlant deal and slashes workforce to cut costs • IH Market News • 04/13/2026 02:06:25 PM
- AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 • PR Newswire (US) • 04/12/2026 11:15:00 AM
- BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year • PR Newswire (US) • 04/08/2026 12:00:00 PM
- Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin • PR Newswire (US) • 04/07/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:00:15 PM
- /C O R R E C T I O N -- AbbVie/ • PR Newswire (US) • 03/31/2026 02:04:00 PM
- Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® • PR Newswire (US) • 03/31/2026 12:05:00 PM
- AbbVie to Host First-Quarter 2026 Earnings Conference Call • PR Newswire (US) • 03/31/2026 12:00:00 PM
